BioVie, Inc. (BIVI)

NASDAQ: BIVI · IEX Real-Time Price · USD
2.95
-0.17 (-5.45%)
Jan 28, 2022 2:13 PM EST - Market open
Market Cap72.64M
Revenue (ttm)n/a
Net Income (ttm)-143.12M
Shares Out24.96M
EPS (ttm)-8.50
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume37,504
Open3.09
Previous Close3.12
Day's Range2.95 - 3.20
52-Week Range2.85 - 46.10
Beta1.99
AnalystsStrong Buy
Price Target18.00 (+518.6%)
Earnings Daten/a

About BIVI

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinica...

IndustryBiotechnology
Founded2013
Employees6
Stock ExchangeNASDAQ
Ticker SymbolBIVI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for BioVie stock is "Strong Buy" and the 12-month stock price forecast is 18.00.

Price Target
$18.00
(518.56% upside)
Analyst Consensus: Strong Buy

News

BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson's Disease

RENO, Nev., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver di...

1 week ago - GlobeNewsWire

BioVie to Participate at the LifeSci Partners 11th Annual Corporate Access Event

RENO, Nev., Dec. 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver d...

1 month ago - GlobeNewsWire

BioVie Announces Partnership with the American Liver Foundation

Campaign to Improve Education on Ascites Due to Liver Cirrhosis and Raise Awareness of BioVie's Phase 2b Study of BIV201 for Refractory Ascites Campaign to Improve Education on Ascites Due to Liver Cirr...

1 month ago - GlobeNewsWire

BioVie Secures Up to a $25.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Op...

RENO, Nev., Dec. 01, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and ...

1 month ago - GlobeNewsWire

BioVie Hosting Key Opinion Leader Webinar on Complications of Advanced Liver Cirrhosis and BIV201 Phase 2b Clinical T...

Thursday, November 11th @ 1:00pm ET Thursday, November 11th @ 1:00pm ET

2 months ago - GlobeNewsWire

BioVie Announces the Appointment of a New Chief Medical Officer

Dr. Joseph M. Palumbo, Distinguished Pharma Industry Veteran, to Oversee Development Programs in Neurodegenerative and Liver Disease Dr. Joseph M. Palumbo, Distinguished Pharma Industry Veteran, to Over...

2 months ago - GlobeNewsWire

Why Did BioVie Shares Jump 21% Today?

The FDA has signed off BioVie Inc's (NASDAQ: BIVI) Phase 2 study assessing NE3107's potential pro-motoric impact in Parkinson's disease patients. The NM201 study is a double-blind, placebo-controlled, s...

3 months ago - Benzinga

BioVie Announces FDA Authorization to Initiate Phase 2 Trials Assessing NE3107's Pro-motoric Activity in Parkinson's ...

SANTA MONICA, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurolo...

3 months ago - GlobeNewsWire

BioVie Hosting Key Opinion Leader Webinar on Neuroinflammation and Insulin Resistance and New Treatment Approaches fo...

SANTA MONICA, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurolo...

3 months ago - GlobeNewsWire

BioVie to Present at Cantor Virtual Global Healthcare Conference

SANTA MONICA, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurol...

4 months ago - GlobeNewsWire

BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit

SANTA MONICA, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurod...

4 months ago - GlobeNewsWire

BioVie Inc. Announces Closing of Public Offering of Common Stock

SANTA MONICA, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurolo...

5 months ago - GlobeNewsWire

BioVie Stock Plunges On $20M Capital Raise Via Equity At Deep Discount Of 38%

BioVie Inc (NASDAQ: BIVI) priced its underwritten public offering of 2.5 million shares at $8.00 per share for gross proceeds of $20 million. The offer price represents a steep discount of 37.7% from th...

5 months ago - Benzinga

BioVie Inc. Announces Pricing of Public Offering of Common Stock

SANTA MONICA, Calif., Aug. 08, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurolo...

5 months ago - GlobeNewsWire

BioVie Inc. Announces Proposed Public Offering of Common Stock

SANTA MONICA, Calif., Aug. 06, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurolo...

5 months ago - GlobeNewsWire

Basis for BioVie's Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimer's Disease Published in Neurodegener...

Pivotal Phase 3 Trial of NE3107 Expected to Commence in Summer 2021 Pivotal Phase 3 Trial of NE3107 Expected to Commence in Summer 2021

6 months ago - GlobeNewsWire

Development of BioVie's NE3107 Asset Featured by the American Diabetes Association

NE3107 Featured in the ADA's Thought Leadership Film Series at Annual Scientific Session NE3107 Featured in the ADA's Thought Leadership Film Series at Annual Scientific Session

6 months ago - GlobeNewsWire

BioVie Added to Russell Microcap® Index

SANTA MONICA, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver disea...

7 months ago - GlobeNewsWire

BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

Chairman Terren Peizer discusses BioVie's late-stage drug pipeline with multiple shots on goal Chairman Terren Peizer discusses BioVie's late-stage drug pipeline with multiple shots on goal

7 months ago - GlobeNewsWire

BioVie Hosting Research & Development Day

SANTA MONICA, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver diseas...

8 months ago - GlobeNewsWire

Moving Average Crossover Alert: BioVie (BIVI)

BioVie (BIVI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

8 months ago - Zacks Investment Research

BioVie Announces Amended Terms for Asset Acquisition from Privately Held NeurMedix

SANTA MONICA, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for chronic debilitating liver di...

8 months ago - GlobeNewsWire

BioVie to Present at 2021 B. Riley Securities' Neuroscience Conference

SANTA MONICA, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver dise...

9 months ago - GlobeNewsWire